Cardiome Pharma Corp., of Vancouver, British Columbia, reported a net loss of $7.2 million, or 53 cents per share, for the fourth quarter of 2013, due largely to an increase in expenses incurred to support commercialization of atrial fibrillation drug Brinavess (vernakalant) and antiplatelet drug Aggrastat (tirofiban).